The purpose of this study is to test whether intensive chemotherapy combined with early, adequate, and intensive use of Rituximab for aggressive B-NHL in children and adolescents can improve the EFS and OS compared with the historical study CCCG-BNHL-2015.
Histology or cytologically confirmed mature B-cell NHL/AL(Burkitt, DLBCL, PMLBL,or aggressive mature B-cell NHL non other specified or specifiable)
Able to comply with scheduled follow-up and with management of toxicity
Signed informed consent
Follicular lymphoma, MALT and nodular marginal zone are not included into this therapeutic study
Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, previous malignancy of any type, or known positive HIV serology.
Evidence of pregnancy or lactation period. Past or current anti-cancer treatment except corticosteroids during less than one week.
Tumor cell negative for CD20
Children's Cancer Group, China
Lead sponsor
Shanghai Children's Medical Center
Collaborator
Nanjing Children's Hospital
Collaborator
Children's Hospital of Soochow University
Collaborator
West China Second University Hospital
Collaborator
Qilu Hospital of Shandong University
Collaborator
Tianjin Medical University Cancer Institute and Hospital
Collaborator
Xiangya Hospital of Central South University
Collaborator
Wuhan TongJi Hospital
Collaborator